Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,021 to 4,040 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Denosumab vs Placebo: Number of Participants With New or Worsening Vertebral Fractures | 31 of 835 55 of 809 | -3.1 points -5.3 to -0.9 | 1,644 | NCT00556374 Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy |
| Denosumab vs Placebo: Number of Participants With New Vertebral Fractures | 27 of 835 49 of 809 | -2.8 points -4.9 to -0.8 | 1,644 | NCT00556374 Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy |
| Rivaroxaban (Xarelto, BAY59-7939) vs Antiplatelet: Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeds | 49 of 826 30 of 818 | 2.3 points 0.2 to 4.4 | 1,644 | NCT02556203 Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes |
| Rivaroxaban (Xarelto, BAY59-7939) vs Antiplatelet: Number of Participants With Composite Bleeding Endpoint of BARC (Bleeding Academic Research Consortium) 2, 3, or 5 Bleeds | 148 of 826 85 of 818 | 7.5 points 4.2 to 10.9 | 1,644 | NCT02556203 Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes |
| Rivaroxaban (Xarelto, BAY59-7939) vs Antiplatelet: Number of Participants With TIMI (Thrombolysis In Myocardial Infarction) Major / Minor Bleeds | 42 of 826 24 of 818 | 2.2 points 0.2 to 4.1 | 1,644 | NCT02556203 Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes |
| Rivaroxaban (Xarelto, BAY59-7939) vs Antiplatelet: Number of Participants With Death or First Thromboembolic Event (DTE) | 105 of 826 78 of 818 | 3.2 points 0.1 to 6.2 | 1,644 | NCT02556203 Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes |
| Rivaroxaban (Xarelto, BAY59-7939) vs Antiplatelet: Number of Participants With Primary Bleeding Event (PBE) | 46 of 826 31 of 818 | 1.8 points -0.3 to 3.9 | 1,644 | NCT02556203 Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes |
| Rivaroxaban (Xarelto, BAY59-7939) vs Antiplatelet: Number of Participants With Net-clinical Benefit | 137 of 826 100 of 818 | 4.4 points 1.0 to 7.8 | 1,644 | NCT02556203 Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes |
| Rivaroxaban (Xarelto, BAY59-7939) vs Antiplatelet: Number of Participants With Cardiovascular Death or Thromboembolic Event | 83 of 826 68 of 818 | 1.7 points -1.1 to 4.5 | 1,644 | NCT02556203 Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes |
| Intervention Arm (HITSystem 2.1) vs Control Arm (Standard of Care): deaths from any cause | 14 of 899 22 of 740 | -1.4 points -3.0 to 0.0 | 1,639 | NCT04571684 Evaluating HITSystem 2.1 to Improve Viral Suppression in Kenya |
| Intervention Arm (HITSystem 2.1) vs Control Arm (Standard of Care): serious adverse events | 41 of 899 41 of 740 | -1.0 points -3.2 to 1.1 | 1,639 | NCT04571684 Evaluating HITSystem 2.1 to Improve Viral Suppression in Kenya |
| 10% Povidone-iodine (1% Free Iodine) in Purified Water vs 4% Chlorhexidine Gluconate (CHG) in Purified Water: deaths from any cause | 19 of 828 7 of 810 | 1.4 points 0.2 to 2.8 | 1,638 | NCT03385304 Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures |
| 10% Povidone-iodine (1% Free Iodine) in Purified Water vs 4% Chlorhexidine Gluconate (CHG) in Purified Water: serious adverse events | 365 of 828 368 of 810 | -1.3 points -6.2 to 3.5 | 1,638 | NCT03385304 Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures |
| Observation vs Treatment: serious adverse events | 12 of 819 13 of 817 | -0.1 points -1.4 to 1.1 | 1,636 | NCT00000125 Ocular Hypertension Treatment Study (OHTS) |
| Physical Activity vs Successful Aging: Persistent Mobility Disability (Assessed Every 6 Months) | 120 of 818 162 of 817 | -5.2 points -8.8 to -1.5 | 1,635 | NCT01072500 The LIFE Study - Lifestyle Interventions and Independence for Elders |
| Physical Activity vs Successful Aging: Major Mobility Disability, Defined as Incapacity to Walk 400 Meters | 246 of 818 290 of 817 | -5.4 points -9.9 to -0.9 | 1,635 | NCT01072500 The LIFE Study - Lifestyle Interventions and Independence for Elders |
| Physical Activity vs Successful Aging: serious adverse events | 404 of 818 373 of 817 | 3.7 points -1.1 to 8.5 | 1,635 | NCT01072500 The LIFE Study - Lifestyle Interventions and Independence for Elders |
| Etanercept vs nbDMARDs: Number of Participants With Chest X-Ray Prior to New Therapy | 183 of 194 742 of 1,441 | 42.8 points 37.9 to 46.4 | 1,635 | NCT01557322 Characterize Patients With Moderately Active Rheumatoid Arthritis (RA) |
| Umbilical Cord Milking - Neonates vs Early Cord Clamping - Neonates: Number of Neonates Treated With Therapeutic Hypothermia (Cooling) | 21 of 829 35 of 806 | -1.8 points -3.7 to -0.0 | 1,635 | NCT03631940 Umbilical Cord Milking in Non-Vigorous Infants |
| Transdisciplinary Approach vs Multidisciplinary Approach: Depressive Symptoms | 20 of 437 59 of 1,195 | -0.4 points -2.5 to 2.3 | 1,632 | NCT03442322 Optimizing Care for Patients With Dementia |
Code
curl "https://conductscience.org/api/comparisons/v1?page=202"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=202
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00556374-6eb12190",
"title": "Denosumab vs Placebo: Number of Participants With New or Worsening Vertebral Fractures",
"summary": "31 of 835 against 55 of 809; risk difference -3.1 points, 95% interval -5.3 to -0.9; NCT00556374, Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy",
"record": "/library/comparisons/NCT00556374-6eb12190",
"nct_id": "NCT00556374",
"kind": "outcome",
"participants": 1644,
"risk_difference": {
"value": -0.030859418369688314,
"lower": -0.05314506126130004,
"upper": -0.009311553620660981
},
"group_1": "31 of 835",
"group_2": "55 of 809",
"difference": "-3.1 points",
"interval": "-5.3 to -0.9",
"trial_title": "Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy"
},
{
"id": "NCT00556374-f6f756b9",
"title": "Denosumab vs Placebo: Number of Participants With New Vertebral Fractures",
"summary": "27 of 835 against 49 of 809; risk difference -2.8 points, 95% interval -4.9 to -0.8; NCT00556374, Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy",
"record": "/library/comparisons/NCT00556374-f6f756b9",
"nct_id": "NCT00556374",
"kind": "outcome",
"participants": 1644,
"risk_difference": {
"value": -0.028233273872526887,
"lower": -0.049365346571367166,
"upper": -0.007900284189497422
},
"group_1": "27 of 835",
"group_2": "49 of 809",
"difference": "-2.8 points",
"interval": "-4.9 to -0.8",
"trial_title": "Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=203",
"request_id": "hpDSbCO5TSV-3DVa"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant